Effect of Moringa Oleifera Leaf on Hemoglobin Levels in Anemia

Anemia of Pregnancy Clinical Trial

Official title:

Effect of Moringa Oleifera Leaf Capsul on Hemoglobin Levels in Anemia: A Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05737862
• Other study ID #: MAGPH-202210.01
• Status: Completed
• Phase: Phase 3
• Start date: April 1, 2022
• Est. completion date: July 30, 2022

Study information

• Verified date: March 2023
• Source: Universitas Padjadjaran
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of this study was to compare the results of hemoglobin levels between pregnant women in the treatment group and the control group. Participants will be subjected to anthropometric measurements, recall of food intake for 1 x 24 hours, check hemoglobin before and after being given the intervention and participants in the treatment group are given moringa leaf capsules and iron tablets while participants in the control group are only given iron tablets. Researchers will compare the final results of hemoglobin levels between the treatment group and the control group

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: July 30, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 15 Years to 50 Years

Eligibility

Inclusion Criteria:

• Pregnant women with 2nd and 3rd trimester of pregnancy
• Pregnant women with mild to moderate anemia At day 90 after treatment

Exclusion Criteria :

• Hypotensive pregnant women
• Pregnant women with Gemelli
• Pregnant women with chronic diseases (hepatitis and HIV)

Related Conditions & MeSH terms

• Anemia
• Anemia of Pregnancy

Intervention

Dietary Supplement:
• Moringa oleifera capsules
In this arm, pregnant mothers receive capsules containing 500 mg of powdered Moringa oleifera leaves which contain 13.09 mg of iron per100 gram. Dose: 2 × 2 capsules per day for 30 days
• iron and folic acid supplements
In this arm, pregnant mothers receive IFA tablets 2 × 1 tablet a day for 30 days. Each IFA tablet contains 400 mcg folic acid and 180 mg Ferrous Fumarate.

Locations

Country	Name	City	State
Indonesia	University Padjajaran	Bandung	West Java

Sponsors (1)

Lead Sponsor	Collaborator
Universitas Padjadjaran

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Haemoglobin (Hb) level	Hb will be meassured twice, before treatment and 30 days after treatment	Day 0 and day 30